These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38618202)

  • 1. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial.
    Lu H; Zhang G; Mao J; Chen X; Zhan Y; Lin L; Zhang T; Tang Y; Lin F; Zhu F; Lin Y; Zeng Y; Zhang K; Yuan W; Liang Z; Sun R; Huo L; Hu P; Lin Y; Zhuang X; Wei Z; Chen X; Yan W; Yan X; Mu L; Lin Z; Tu X; Tan H; Huang F; Hu Z; Li H; Li G; Fu H; Yang Z; Chen X; Wang FS; Zhong N
    EClinicalMedicine; 2024 May; 71():102582. PubMed ID: 38618202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Zhang H; Zhou J; Chen H; Mao J; Tang Y; Yan W; Zhang T; Li C; Chen S; Li G; Zhang G; Ding Y; Liu L
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0111523. PubMed ID: 38099673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function.
    Zhou J; Zhang H; Chen H; Zhang G; Mao J; Zhang T; Tang Y; Yan W; Li C; Ding Y; Jin Q
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0053924. PubMed ID: 38990016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.
    Zhan Y; Lin Z; Liang J; Sun R; Li Y; Lin B; Ge F; Lin L; Lu H; Su L; Xiang T; Pan H; Huang C; Deng Y; Wang F; Xu R; Chen D; Zhang P; Tong J; Wang X; Meng Q; Zheng Z; Ou S; Guo X; Yao H; Yu T; Li W; Zhang Y; Jiang M; Fang Z; Song Y; Chen R; Luo J; Kang C; Liang S; Li H; ; Zheng J; Zhong N; Yang Z
    EClinicalMedicine; 2024 Jan; 67():102359. PubMed ID: 38188690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.
    Wang F; Xiao W; Tang Y; Cao M; Shu D; Asakawa T; Xu Y; Jiang X; Zhang L; Wang W; Tang J; Huang Y; Yang Y; Yang Y; Tang R; Shen J; Lu H
    Lancet Reg Health West Pac; 2023 Sep; 38():100835. PubMed ID: 37484496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
    Fan X; Dai X; Ling Y; Wu L; Tang L; Peng C; Huang C; Liu H; Lu H; Shen X; Zhang W; Wang F; Li G; Li M; Huang Y; Zhang H; Li M; Ren F; Li Y; Liu C; Zhou Z; Sun W; Yi Y; Zhou D; Gao H; Pan Q; Liu H; Zhao J; Ding Z; Ma Y; Li W; Wang Q; Wang X; Bai Y; Jiang X; Ma J; Xie B; Zhang K; Li L
    Lancet Infect Dis; 2024 Feb; 24(2):129-139. PubMed ID: 38006892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial.
    Wang B; Li HJ; Cai MM; Lin ZX; Ou XF; Wu SH; Cai RH; Wei YN; Yang F; Zhu YM; Yang ZF; Zhong NS; Lin L
    EClinicalMedicine; 2023 Sep; 63():102189. PubMed ID: 37692076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    Cao B; Wang Y; Lu H; Huang C; Yang Y; Shang L; Chen Z; Jiang R; Liu Y; Lin L; Peng P; Wang F; Gong F; Hu H; Cheng C; Yao X; Ye X; Zhou H; Shen Y; Liu C; Wang C; Yi Z; Hu B; Xu J; Gu X; Shen J; Xu Y; Zhang L; Fan J; Tang R; Wang C
    N Engl J Med; 2024 Jan; 390(3):230-241. PubMed ID: 38231624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.